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Background: Using surrogate end points for overall survival, such as disease-free survival, is increasingly common in
randomized controlled trials. However, the definitions of several of these time-to-event (TTE) end points are imprecisely
which limits interpretation and cross-trial comparisons. The estimation of treatment effects may be directly affected by the
definitions of end points. The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer
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trials) aims to provide recommendations for definitions of TTE end points. We report guidelines for randomized cancer
clinical trials (RCTs) in breast cancer.
Patients and methods: A literature review was carried out to identify TTE end points (primary or secondary) reported
in publications of randomized trials or guidelines. An international multidisciplinary panel of experts proposed recommen-
dations for the definitions of these end points based on a validated consensus method that formalize the degree of agree-
ment among experts.
Results: Recommended guidelines for the definitions of TTE end points commonly used in RCTs for breast cancer are
provided for non-metastatic and metastatic settings.
Conclusion: The use of standardized definitions should facilitate comparisons of trial results and improve the quality of
trial design and reporting. These guidelines could be of particular interest to those involved in the design, conducting,
reporting, or assessment of RCT.
Key words: guidelines, randomized, controlled trial, time-to-event end point, efficacy measure, breast cancer
introduction
In randomized cancer clinical trials (RCTs), the validated and
most objectively defined evaluation criterion is overall survival
(OS), characterized as the time from randomization to patients’
death (all causes). The development of new cytotoxic agents,
the current context of strategic trials, and the multiplication of
lines of treatment, especially in breast cancer, have significantly
reduced mortality in certain contexts. This therapeutic progress
has resulted in the need for surrogate end points and/or inter-
mediate end points for OS. Such end points are being increas-
ingly used in cancer RCTs. Thus, disease-free survival (DFS)
and progression-free survival (PFS) have been used as surrogate
end points of OS in non-metastatic and metastatic settings, re-
spectively. These surrogate end points are gradually replacing
OS [1] and their development has been strongly influenced by
the need to reduce the number of patients taking part in RCTs,
as well as the duration and, ultimately, the cost of RCTs.
As recommended by the International Conference on
Harmonisation (ICH) guidelines [2] and by the CONSORT state-
ment [3], each time-to-event (TTE) end point should be precisely
defined. It implies specifying the date of origin, the list of events to
be considered, such as failures, and the censoring process. However,
despite their extensive use, most TTE end points are often poorly
defined, and when a definition is provided, it varies from one publi-
cation to another as underlined by a recent study published in the
Journal of Clinical Oncology [4] and by the Food and Drug
Administration (FDA) [5]. As an example, in a review of RCT in
oncology, Mathoulin-Pélissier et al. [4] showed that a clear defin-
ition of survival end points was reported for only 52% of cancer
RCTs published in major journals. The heterogeneity of definitions
for TTE end points was recently highlighted by the international
community, as demonstrated by all the publications recommending
the definition of specific criteria and/or the preferred use of certain
criteria in specific localizations such as for colorectal cancer in the
adjuvant setting [6], hepatocellular carcinoma [7], lymphoma [8],
or breast cancer [9]. However, most of these recommendations
were usually based on experts’ opinions, without formal inter-
national consensus process, and without representation of academic
groups in the selected panels of experts, facts that may explain why
they have not been widely accepted in current practice.
It is important to distinguish the process of selecting a rele-
vant end point from the action of defining this same end point.
The selection of TTE end points to assess a therapeutic strategy
depends on the characteristics of a given trial including settings
(adjuvant versus metastatic) and treatments (systemic, local, or
any combination thereof). As such, the choice of the end points
is trial-specific. Once the end point is identified, it then has to
be appropriately defined, ideally using a standardized definition
to enable future comparisons.
Using a formal consensus process, we set up the international
DATECAN initiative (Definition for the Assessment of Time-
to-event Endpoints in CANcer trials) [10], which aimed to
obtain standardized consensus definitions of TTE end points
for multiple cancer sites: breast; sarcomas/gastro intestinal
stromal tumors (GISTs); pancreas; stomach/esophagus; head
and neck; colon/rectum; kidney/bladder; and lung cancers.
Here, we report guidelines for the definition of TTE end points
used in breast cancer RCT as primary or secondary end points.
methods
The DATECAN project was launched in 2010 regarding three
cancer sites: breast, sarcoma/GIST, and pancreatic cancer. The
coordinating committee (CC) for the breast cancer part of
the project included two experts (SG-B and TSD-Y).
consensus process
A formal consensus method was used to develop these guide-
lines [11, 12]. Its purpose was to formalize the degree of agree-
ment among experts using iterative ratings with feedbacks to
identify and select points on which there was either disagree-
ment or uncertainty. The guidelines were subsequently based on
the agreement scores. The formal consensus method involved
the following steps (Figure 1): (i) the assessment of the evidence
with regard to the research question; (ii) the elaboration fol-
lowed by the pre-testing of the questionnaire before collecting
experts’ opinions; (iii) the scoring of the questionnaires; (iv) the
analysis of the experts’ opinions and the drafting of the final
report; (v) the peer-review step; and (vi) the diffusion of the
recommendations. An overview of these steps is provided in
supplementary Material S1, available at Annals of Oncology
online. A full description of the methodology of the consensus
process has been published in a former study [10].
literature review
We conducted literature reviews to assess the development of
guidelines for TTE end points and listed TTE end points
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commonly reported in an RCT, either as primary or secondary
end points. The research algorithms used are available in sup-
plementary Material S2, available at Annals of Oncology online.
questionnaires
All experts had to fill in a first questionnaire: they all received
the same questionnaire to score each TTE end point on a scale
of 1 (totally disagree) to 9 (totally agree), according to whether
various clinical events should be regarded as events in the defin-
ition of TTE outcomes. After the first round, the second ques-
tionnaire was personalized for each expert (supplementary
Material S3, available at Annals of Oncology online).
Items for which a strong consensus had been reached after the
first questionnaire were highlighted. For items with no consensus
found, the distributions of scores obtained during the first round
were summarized (minimum, maximum, and median scores)
and the initial score of the RC expert was indicated. In second
questionnaire, experts were asked to re-score the items for which
no consensus had been reached in the first round.
results
selection of TTE end points to be defined
and clinical events of interest
Eleven end points were selected from the literature, according to
the trial setting (non-metastatic [9] or metastatic [2]) and for
which no consensus methodology in adjuvant settings had been
described [9]. Clinical events, which could be included in the
definition of these end points, were identified (Table 1).
experts for the scoring process
The CC drafted a list of 50 experts from European countries to
include in the rating committee, meeting twice. Because of an
over-selection of French experts at the first selection step, we
opened the scoring process to additional experts from other
Europeans countries. Of the 35 experts who filled-in the first
questionnaire, 31 (89%) also answered the second questionnaire.
They were specialists in medical oncology (n = 14; 45%), radi-
ation oncology (n = 4; 13%), surgery (n = 4; 13%), pathology
(n = 4; 13%), and methodology/biostatistics (n = 5; 16%; supple-
mentary Material S4, available at Annals of Oncology online).
These experts worked in institutions from many countries, such
as France, Belgium, UK, the Netherlands, Portugal, Italy,
Germany, Denmark, Slovenia, and Switzerland. They belonged
to various cooperative groups including breast cancer groups
from the EORTC (European Organization for Research and
Treatment of Cancer), UNICANCER (French Group of
Comprehensive Cancer Centers), the American Society for
Radiation Oncology (ASTRO), the French Society for Radiation
Oncology (SFRO), and from the National Cancer Research
Institute Breast Cancer Group of the United Kingdom (NCRI),
the Dutch Breast Cancer Trialists’ Group (BOOG), and the
Italian Breast Cancer Group.
Final report and diffusion
of the guidelines
(SC + RC)
Formal consensus method
(Delphi method)
for each cancer site
Experts/panellists selection
- SC (steering committee)
- RC (rating committee)
Problem definition
(SC expert sofficitation + synthesis of merature)
- RC (rating committee)
Development and diffusion of
questionnaire (SC)
First-round rating process
(RC - by mail)
Analysis and synthesis of the
questionnaires
(SC)
In-person meeting lead by the SC:
Presentation to the RC of the results
SC: Steering Committee
RC: Rating Committee
Figure 1. A modified Delphi method used in the DATECAN initiative to reach consensus for time-to-event end points in randomized, controlled trials for
breast cancer.
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consensus rates after the two rounds of rating
The consensus process was constituted of two rounds of rating
(first round: January 2011 to January 2012; second round:
February 2012 to May 2012) and one face-to-face meeting
(3 June 2012, Chicago). During the first round, experts were
asked to rate a total of 150 events pertaining to 11 TTE end
points. At that step, a strong consensus was reached for 6 (4%)
of the events for two end points. After the second round, a
strong consensus was reached for 60 events (42%), and strong or
relative consensus was reached for 80 events (56%). After the
two steps of rating process, no consensus was reached for 70
events covering the 11 end points. Those events were thus dis-
cussed at the face-to-face meeting.
face-to-face meeting
Before discussing each event on an individual basis and with the
aim of harmonization, experts present at the meeting first took a
number of decisions. The aim of this preliminary discussion was
triple: to select the items that would be discussed, to maintain
the consensus process even though not all experts attended the
meeting and some experts were therefore unavailable for
discussion, and to decide the procedure to adopt in case of an
absence of consensus.
standardized definitions of the TTE end points
Table 2 lists the events that need to be included in the definition
of each TTE end point following the consensus process, depend-
ing on the disease setting (non-metastatic, metastatic, or both
settings).
Among the 11 end points initially listed, one was considered
ambiguous (DFS) and renamed by the experts as invasive DFS,
iDFS.
Two definitions for two different end points were identical:
distant DFS (D-DFS) and distant relapse-free survival (D-RFS).
The reference date was usually the date of randomization, but
it could also be the date of diagnosis or treatment initiation, de-
pending on the study. End points were defined according to the
setting. Nine end points were specifically defined for the non-
metastatic setting: breast cancer-specific survival (BCSS), iDFS,
D-DFS, D-RFS, RFS, locoregional RFS (L-RFS), recurrence-free
interval (RFi), breast cancer-free interval (BCFi), and distant re-
currence-free interval (D-RFi). Two end points were designed
for the metastatic setting: PFS and time-to-progression (TTP).
validation of the guidelines and peer-review
The minutes of the face-to-face meeting, which included the
final guidelines, were validated by email by all the 31 participat-
ing experts and then submitted to a peer-review group for exter-
nal comments. This group provided a formal, advisory opinion
on the content and form of the initial version of the guidelines,
in particular their applicability, acceptability, and readability.
discussion
In RCTs, standardized definitions of the TTE end points should
be adopted to enable consistent interpretation of trial results and
facilitate cross-trial comparisons and meta-analyses. Clinical trial
end points often refer to efficacy, adverse events, or quality of
life. In early breast cancer, effective methods of early diagnosis
and new treatments have led to a longer expected survival for
patients. Therefore, it is not convenient to use OS as a primary
end point for many clinical trials, especially those conducted in
a non-metastatic setting. Many other end points have been used
to accelerate the development of news drugs and treatments, but
with a lack of consistency between the different definitions used
in the studies. It is therefore necessary to standardize end points
to ensure the uniformity of data collection among the studies.
This will make trials more useful and facilitate their implemen-
tation.
A given end point should always encompass the same set of
events, as clearly highlighted by Hudis et al. [9]. However,
though OS has been recognized as the least ambiguous and the
most clinically relevant end point in cancer clinical trials, the
other end points often used as secondary end points need to be
standardized. For example, in two adjuvant clinical trials asses-
sing the efficacy of aromatase inhibitors, the event ‘second
primary invasive non-breast cancer’ was included for the same
primary end point in the first trial [13] but not in the second
[14]. This raises the possibility that a treatment could be
Table 1. Time-to-event end points considered for the elaboration
of definitions and clinical events that could possibly be included
in their definitions
Time-to-event end points
Breast cancer-specific survival (BCSS)
Invasive disease-free survival (iDFS)a
Distant disease-free survival (D-DFS)
Distant relapse-free survival (D-RFS)
Relapse-free survival (RFS)
Locoregional relapse-free survival (L-RFS)
Recurrence-free interval (RFi)
Breast cancer-free interval (BCFi)
Distant recurrence-free interval (D-RFi)
Progression-free survival (PFS)
Time-to-progression (TTP)
Clinical events
Invasive ipsilateral breast tumor recurrence/progression
Local invasive recurrence/progression
Regional invasive recurrence/progression (M+: Regional
progression)
Invasive contralateral breast cancer
Appearance/occurrence of metastases/distant recurrence
Second primary invasive cancer (non-breast cancer)
Death from breast cancer
Death from non-breast cancer cause
Death related to protocol treatment
Death from any cause
Death from unknown cause
Ipsilateral DCIS
Contralateral DCIS
Lost to follow-up
aInitially named ‘disease-free survival’ and renamed by the experts.
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Table 2. DATECAN guidelines for clinical events to be included in the definitions of time-to-event end points in randomized clinical trials assessing treatments for breast cancer
Setting Recommended
Time-to-event
end point
Causes of death included in definition Clinical events included in definitions
From
breast
cancer
From non-
breast cancer
cause
Related to
protocol
treatment
From
any
cause
From
unknown
cause
Invasive
ipsilateral
breast tumor
recurrence/
progression
Local
invasive
recurrence/
progression
Regional
invasive
recurrence/
progression
(M+: regional
progression)
Invasive
contra lateral
breast cancer
Appearance/
occurrence of
metastases/
distant
recurrence
Second
primary
invasive
cancer
(non-
breast
cancer)
Ipsilateral
DCIS
Contra
lateral
DCIS
Non- metastatic BCSS X NC
iDFS X X X X X X X X X X X X X
D-DFS X X X X X X
D-RFS X X X X X X
RFS X X X X X X X X X X
L-RFS X X X X X X X X X
RFi X X X X X X
BCFi X X X X X X X X
D-RFi X X
Metastatic PFS X X X X X NA NA X X
TTP X NA NA X X
It was recommended not to include the following events in any of the time-to-event end points: loss to follow-up.
BCSS, breast cancer-specific survival; iDFS, invasive disease-free survival; D-DFS, distant disease-free survival; D-RFS, distant relapse-free survival; RFS, relapse-free survival; L-RFS, locoregional relapse-
free survival; RFi, recurrence-free interval; BCFi, breast cancer-free interval; D-RFi, distant recurrence-free interval; PFS, progression-free survival; TTP, time-to-progression; NC, no consensus.
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declared effective or inefficient depending on the definition
used for the end point of the study. Birgisson et al. [15] and
Nout et al. [16] showed in colorectal [15] and breast cancer
[16] patients, respectively, that defining properly TTE end
points is a central issue when designing trials since it may
affect the estimation of treatment effect, the statistical power,
and thus the final interpretation of the trial, as highlighted for
respectively.
For breast cancer, Hudis et al. [9] proposed standardized defi-
nitions for many end points used in the adjuvant setting.
However, these definitions of the TTE end points were based on
recommendations made by an expert group in the absence of
any formal international consensus method, which therefore
limited their use and acceptability in current practice. Moreover,
to our knowledge, no definition of TTE end points has so far
been proposed for metastatic breast cancer. We thus decided to
use a formal consensus methodology for the consensus process
that resulted in the elaboration of standardized definitions and
recommendations regarding 11 TTE end points specifically for
breast cancer clinical trials. Our initial list of TTE end points
was established following selected end points from published
recommendations by an expert group or a literature review of
recent randomized trials.
After the first round of rating, which involved 35 international
experts from various medical specialties, a strong consensus was
reached for only 4% of the items. After the second round of
rating, the extremely low initial consensus rate went up to a
strong or relative consensus for 80 events (56%). The lack of
initial consensus highlighted the disparity of expert opinions
and the need for harmonization despite the definitions already
available for the adjuvant setting (Hudis et al. for the STEEP
group) [9]. The main cause of the improvement in the consen-
sus rates may be related to the design of the consensus process.
The formal consensus process aimed to guide experts into
taking position, while allowing them to maintain their opinion
at each scoring round. Another reason for such an improvement
may be the different rules used to define the consensus after
each round: rules for the second round were slightly relaxed to
ensure that the systematic exclusion of a proposal by a rater
would block the consensus process [10, 11].
Moreover, the initial low consensus rate might probably also
be due to misinterpretation of the text and tables. Clarification
of the remaining issues at the face-to-face meeting led to a con-
sensus for all the events except one, the ‘death related to proto-
col treatment’ event, in the definition of the end point ‘BCSS’.
The consensus process also underlined some irrelevant end-
points. Indeed, during the face-to-face meeting, the experts con-
sidered DFS irrelevant in the context of breast cancer. They
suggested using ‘iDFS’ instead of DFS, from in situ carcinoma
that should be excluded, as recommended also by Hudis et al.
One surprising result after the face-to-face meeting was the con-
clusion that the definitions for two different end points, D-DFS
and D-RFS, should be identical. These results also questioned
the relevance of some end points. The list of outcomes was
based on our literature review with the objective to propose a
large panel of definitions, so that researchers will find a standar-
dized definition for the outcome that best suits the objective of
their study. As D-DFS is more often used that D-RFS, in future
trials, we recommend that D-DFS should be preferred to D-RFS
and that a precise definition of D-RFS should be given in trials
that will use this end point.
For ‘invasive contralateral breast cancer’ and ‘second primary
invasive cancer (non-breast cancer)’ events, the experts adopted
a conservative approach and assumed that these two events were
new primary cancers unless it was proved that they were a me-
tastasis of the studied disease. These two events were therefore
not included in any end point except ‘breast cancer-free interval’
for invasive contralateral breast cancer and DFS (iDFS) for
‘second primary invasive cancer (non-breast cancer)’.
Some recommendations were made during the face-to-face
meeting. First, lost-to-follow-up should not be included in any
of the previously described end points, and should be censored
at the time of the status last known. Second, all deaths, whatever
the cause, should be considered events for ‘survival end points’,
except for cancer-specific survival (CSS) in which ‘death from
breast cancer’ was proposed for inclusion. No consensus was
reached for ‘death related to protocol treatment’, probably due
to the difficulty to define precisely a death ‘related to protocol
treatment’. Regarding the lack of consensus for the event ‘death
related to protocol treatment’, a recommendation was made
that, in future trials, this end point should be clearly defined by
referring to all the events that it includes.
One possible weakness of the consensus process is that it did
not take into account rules relating to the censoring process. In
this study, we have chosen to focus on recommendations about
the definition of the end points and not on the recommenda-
tions about the censoring process or on the data collection pro-
cedures. When a clinical event is not included in a definition, it
can be censored, ignored, or accounted for (using competing-
risk analysis) in the statistical analysis, and the selected method
will be study-specific depending on the objectives. Providing
guidelines for events to be censored or ignored at the analysis
stage is not straightforward and requires both the censoring/ig-
noring of events in each trial and the precise definition of the
impact of the censoring process on the estimation of the treat-
ment effect [16]. We deliberately did not address the issue
related to the data collection procedures (evaluation schedules
and criteria) to achieve the actual calculations of the end points
defined in the manuscript with a uniform fashion. However,
the measurement tools (such as the surveillance schedule, the
imaging techniques, etc.) must be defined by the study while
accounting for the evolution of the conceptual elements to
be included in the definitions of the end points. Just like the de-
velopment of standardized definitions, these issues could be
addressed with consensus processes using different independent
trials’ scenarios (disease, setting, and treatment).
Comparison of the guidelines for the definitions of TTE end
points commonly used in RCTs for breast cancer with those
proposed for sarcoma/GIST and pancreatic cancers showed that
similar definitions were used for all the TTE end point. For
example, the three most commonly used TTE end points, such
as PFS, TTP, and DFS, share exactly the same definitions across
these tumor sites. Some slight differences did appear, however.
First, some TTE end points can be defined for a specific cancer
type. For example, disease-specific survival was proposed only
for sarcoma/GIST, whereas pancreas and breast cancer guide-
lines defined a CSS. Similarly, time to deterioration in quality of
life was defined for pancreas cancer, but not for sarcoma/GIST
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and breast cancers. Second, a TTE end point can include the
same events, but be named differently, e.g. ‘distant metastasis-
free survival’ which is called ‘distant-DFS’ in breast cancer.
The major strength of our study lies in the formal consensus
methodology used, which resulted in the elaboration of standar-
dized definitions and recommendations regarding 11 TTE end
points designed specifically for breast cancer RCT. The partici-
pation of many international experts in the consensus process
increased the likelihood that these recommendations for early
and metastatic breast cancer would be accepted by the scientific
community, and as such contributed to their generalizability,
their acceptability, and their wide-scale implementation in
future research in breast cancer.
conclusion
The DATECAN initiative was set up with the objective to provide
guidelines for standardized definitions of TTE end points in RCTs
for different cancer sites, including pancreatic and sarcoma/GIST
cancers, for which guidelines have already been finalized as well.
Here, we have provided consensus definitions for the most com-
monly used end points in breast cancer clinical trials in both early
and metastatic settings. The availability of these guidelines should
improve international comparisons of trial results as well as meta-
analyses. These recommendations should be disseminated for ac-
quisition and endorsement by researchers and academic groups
participating in clinical research. In addition, these guidelines
should be of interest to other potential users including reviewers
and editors of scientific journals, who have recently shown
increased interest in the quality of the reporting of clinical trials
[4, 15], regulatory authorities [5], and any research scientist body
interested in improving outcome measurements and reporting of
clinical trials [17]. Progress in this field also depends on the collec-
tion and publication of detailed data on the distinct clinical events
that contribute to the TTE end points.
The future perspectives of the DATECAN initiative and
ongoing work include extending the consensus procedure to
other cancer sites (current project in stomach/esophagus,
kidney, bladder, head and neck, colon, and lung cancers), asses-
sing the impact of these definitions on academic cancer RCTs,
evaluating the statistical properties of the newly defined inter-
mediate end points (in particular PFS and DFS) as surrogates
for OS, and extending the consensus to other countries (North
America, India, South-east Asia, and Australia) for a worldwide
view. This work is expected to provide insights into the per-
formance of these end points to adequately capture treatment
effects depending on the disease, the setting (adjuvant or meta-
static), and the treatment (local, cytotoxic, or cytostatic).
acknowledgements
The authors thank Pippa McKelvie-Sebileau for medical editor-
ial assistance, and Philip Bastable and Hélène de-Forges for
editing the manuscript.
funding
This work was supported by grants from the French National
League against Cancer (Ligue Nationale Contre le Cancer, 2009
National Grant for Clinical Research) and the French National
Cancer Institute (Institut National du Cancer - INCa, financial
support for organizing the in-person meeting held in Chicago)
(no grant number).
disclosure
The authors have declared no conflicts of interest.
references
1. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug
Administration approval of oncology drugs. J Clin Oncol Off J Am Soc Clin Oncol
2003; 21(7): 1404–1411.
2. International conference on harmonisation; guidance on statistical principles for
clinical trials; availability—FDA. Notice. Fed Regist 1998; 63(179): 49583–49598.
3. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for
reporting parallel group randomized trials. Ann Intern Med 2010; 152(11): 726–732.
4. Mathoulin-Pélissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival end
point reporting in randomized cancer clinical trials: a review of major journals.
J Clin Oncol Off J Am Soc Clin Oncol 2008; 26(22): 3721–3726.
5. Food and Drugs Administration DoHaHS. Guidance for Industry Clinical Trial
Endpoints for the Approval of Cancer Drugs and Biologics. Rockville: US
Department of Health and Human Services Food and Drug Administration 2007.
6. Punt CJA, Buyse M, Köhne C-H et al. Endpoints in adjuvant treatment trials: a
systematic review of the literature in colon cancer and proposed definitions for
future trials. J Natl Cancer Inst 2007; 99(13): 998–1003.
7. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in
hepatocellular carcinoma. J Natl Cancer Inst 2008; 100(10): 698–711.
8. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant
lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 2007; 25(5): 579–586.
9. Hudis CA, Barlow WE, Costantino JP et al. Proposal for standardized definitions for
efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol
Off J Am Soc Clin Oncol. 2007; 25(15): 2127–2132.
10. Bellera CA, Pulido M, Gourgou S et al. Protocol of the Definition for the
Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project:
formal consensus method for the development of guidelines for standardised time-
to-event endpoints’ definitions in cancer clinical trials. Eur J Cancer Oxf Engl 1990
2013; 49(4): 769–781.
11. Fitch K. The Rand/UCLA Appropriateness Method User’s Manual. Santa Monica:
RAND 2001.
12. Haute Autorité de la Santé. Élaboration de recommandations de bonne pratique
Méthode “Recommandations pour la pratique clinique”. 2010.
13. Thurlimann B et al. The Breast International Group (BIG) 1-98 collaborative group.
N Engl J Med 2005; 353: 2747–2757.
14. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with
endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant
tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;
366(9484): 455–462.
15. Birgisson H, Wallin U, Holmberg L, Glimelius B. Survival endpoints in colorectal
cancer and the effect of second primary other cancer on disease free survival.
BMC Cancer 2011; 11: 438.
16. Nout RA, Fiets WE, Struikmans H et al. The in- or exclusion of non-breast cancer
related death and contralateral breast cancer significantly affects estimated outcome
probability in early breast cancer. Breast Cancer Res Treat 2008; 109(3): 567–572.
17. COMET Initiative. http://www.comet-initiative.org (1 June 2014, date last
accessed).
doi:10.1093/annonc/mdv106 | 
Annals of Oncology review
